Failure to Monitor Anticoagulant Therapy for Signs of Bleeding
Summary
The facility failed to ensure that a resident receiving apixaban, an anticoagulant, was monitored for side effects of bleeding as required by the resident’s care plan and facility policy. The resident was admitted with diagnoses including acute kidney failure, pulmonary embolism with acute cor pulmonale, and a history of falls, and had a physician’s order for apixaban 5 mg by mouth twice daily for pulmonary embolism/DVT. The resident’s history and physical documented that the resident did not have capacity to understand and make decisions, and the MDS showed moderately impaired cognitive skills and a need for maximum assistance with toileting, showering, dressing, and personal hygiene. The care plan for anticoagulant therapy directed staff to monitor for side effects and effectiveness and to monitor, document, and report adverse reactions such as blood-tinged urine, black tarry stools, dark or bright red blood in stools, sudden severe headaches, nausea, vomiting, diarrhea, muscle or joint pain, lethargy, and bruising. Review of the MAR for the month of April showed that the resident received apixaban twice daily from the 1st through the 13th, but there was no documented monitoring for bleeding or other side effects associated with apixaban. During an interview and concurrent record review, the DON acknowledged that apixaban is an anticoagulant with side effects of bleeding and bruising, and stated that the resident should have been monitored for bleeding every shift with documentation on the MAR. The DON confirmed that such monitoring was not documented. The facility’s anticoagulation clinical protocol required assessment for signs or symptoms of adverse drug reactions and monitoring for possible complications in individuals on anticoagulation, including nursing evaluation and communication with the physician if there was evidence of bleeding. Despite these requirements, there was no documentation that staff monitored or assessed this resident for bleeding while the resident was receiving apixaban.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.